[e-farmacos] WHO Pharmaceut Newsletter, n 6 , 2007

[mmadurga@agemed.es]

Estimadas y estimados,

La WHO acaba de publicar el ultimo numero del WHO Pharmaceuticals
Newsletter, n 6 , 2007, con el siguiente indice:

TABLE OF CONTENTS

Regulatory Matters
Aprotinin -- Temporary suspension while awaiting review of BART-study
mortality data... 1
Carisoprodol -- Suspended due to greater risks than benefits... 1
Desmopressin -- Risk of hyponatraemia and seizures; intranasal formulations no longer indicated in PNE... 1
Eltroxin tablets -- New formulations that should not be halved or crushed..1
Erythropoiesis stimulating agents -- Labels to address risks to cancer and chronic kidney failure patients ... 2
Lumiracoxib -- Suspended in the United Kingdom due to risk of liver damage ...2
Mycophenolate mofetil -- Revised as Category D drug, to reflect risk of
fetal harm ...2
Rosiglitazone -- Revised prescribing information due to adverse cardiac
events ...3
Safety of Medicines
Cefepime -- Reports of death being investigated ...4
Clozapine -- Constipation could be fatal ...4
Glitazones -- Fluid retention, cardiac failure and macular oedema
........ 4
Inhaled long acting beta agonists -- Risk of serious asthma
exacerbations... 5
Quinolone antibiotics -- Tendon disorders ...5
Tramadol -- Seizures and serotonin syndrome ...5
Warfarin -- Potential for interactions ...6
Feature
Thirtieth annual meeting of representatives of national centres
participating in the WHO Programme for International Drug Monitoring,
10-13 October 2007: recommendations from working groups...7
Nimesulide: national and EU review and regulatory outcome ...11

Proximamente se podra consultar en la web:
http://www.who.int/medicines/publications/newsletter/en/  

Un abrazo y un feliz 2008,

Mariano Madurga Sanz
Jefe de Servicio de Coordinacion del SEFV
Division de Farmacoepidemiologia y Farmacovigilancia
Agencia Espanhola de Medicamentos y Productos Sanitarios
mmadurga@agemed.es